What Iowa and New Hampshire tell us about Medicare-for-All

In this Axios column, Drew Altman analyzes data from the New Hampshire exit poll showing that support for Medicare-for-all played a role in the primary while broader support for a more moderate plan may be a signal about the general election.

Column Read Post

JAMA Forum: Don’t Be Surprised if the Next Big Health Care Debate Is About Drug Prices

In this post for The JAMA Forum, Larry Levitt examines both the Democratic candidates’ proposals and the Trump administration’s record on lowering drug prices, which remains a top issue for the public with bi-partisan support. 

Column Read Post

Self-insured Companies Do No Better on Cost Control

A data surprise? Drew Altman, in his latest Axios column, shows there is no difference between large self-insured and fully insured companies when it comes to controlling health care costs, bucking conventional wisdom.

Column Read Post

The ACA is Doing Fine Without a Mandate Penalty

In an Axios column, Drew Altman explains that the elimination of the Affordable Care Act’s individual mandate penalty has had little impact on how the ACA’s insurance markets are working, showing that “the marketplaces continue to function, even when ‘severed’ from the mandate penalty,” and undercutting a central argument in the lawsuit seeking to strike down the entire law.

Column Read Post

Health Policy in 2020 Will Be Made in the States

With a questionable outlook for 2020 passage of legislation on prescription drug pricing and surprise medical bills, Drew Altman says the real action to watch in health policy is likely to be in the states.

Column Read Post

Private Insurance’s Costs are Skyrocketing

In this Axios column, Drew Altman takes a long-term view of the recently released federal data on health spending showing that spending for private insurance is rising much faster than for Medicare and Medicaid, and predicts rising pressure in the health care industry as a result. 

Column Read Post